Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2014 (2014), Article ID 484563, 4 pages
Case Report

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor

1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2Division of Hematology, Department of Medicine, The Johns Hopkins Hospital, 1830 E. Monument Street, Suite 7300, Baltimore, MD 21205, USA
3Department of Pathology, The Johns Hopkins Hospital, 1800 Orleans Street, Sheikh Zayed Tower B1-1065, Baltimore, MD 21287, USA

Received 24 March 2014; Accepted 27 April 2014; Published 14 May 2014

Academic Editor: Kiyotaka Kawauchi

Copyright © 2014 Nicholas B. Abt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. We present the case of a 73-year-old female, with no family or personal history of a bleeding disorder, who had a classic presentation for acquired hemophilia A. Factor VIII activity was low but detectable and a factor VIII inhibitor was undetectable. Methods. The patient’s plasma was comprehensively studied to determine the cause of the acquired coagulopathy. Using the Nijmegen modification of the Bethesda assay, no factor VIII autoantibody was measureable despite varying the incubation time from 1 to 3 hours. Results. The aPTT was prolonged at 46.8 seconds, which did not correct in the 4 : 1 mix but did with 1 : 1 mix. Using a one stage factor VIII activity assay, the FVIII activity was 16% and chromogenic FVIII activity was also 16%. The patient was treated with recombinant FVII and transfusion, significantly reducing bleeding. Long-term therapy was initiated with cyclophosphamide and prednisone with normalization of FVIII activity. Conclusions. Physicians can be presented with the challenging clinical picture of an acquired factor VIII inhibitor without a detectable inhibitor by the Bethesda assay. Standard therapy for an acquired hemophilia A should be considered.